CD274 and cervical carcinoma: In addition to these tumor-agnostic indications, since December 2022, cemiplimab monotherapy (anti-programmed cell death 1 antibody) has been approved in recurrent cervical cancer as a second-line or later treatment in Japan, regardless of PD-L1 status [15].